Although solid dosage forms like tablets and capsules continue to dominate the global pharmaceutical market, many people find them challenging to take. There is evidence to suggest that oral liquid dosage forms may offer untapped opportunities, with the potential to: improve patient experiences and compliance reduce healthcare costs create new revenue streams. In a study[…]
Don’t Ignore the Market Opportunities of Oral Liquid Dosage Forms
blog, Case Study, LGM Pharma Tags: dosage formLGM Pharmaliquid doseoral Apr 04, 2021
Reshoring Early-Stage Pharma
blog, Supply Chain Tags: APIsCOVID-19reshoringrisk mitigationsupply chain Feb 28, 2021
The Emergence of a Post COVID-19 Risk Mitigation Strategy Over the last few decades, pharma companies serving the U.S. market have moved most of their production and API manufacturing overseas. There were obvious incentives at the time. Offshore operations could deliver significant cost savings, even after factoring in the expense of shipping product to the[…]
Semi-Solids: Don’t Underestimate the Potential (or the Challenges)
blog Tags: burnsdiabetesinfectionpersonalized medicinesemi-solidskin diseaseSSDtopical Jan 31, 2021
For decades, the most popular form of drug dosage has consistently remained oral solids —the tablet, the pill, the capsule. This trend is likely to continue, but the oral solid’s unassuming younger sibling – the semi-solid dose (SSD) – is making some noise. The semi-solids market is growing, and will continue to grow, over[…]
2 Key Factors to Accelerate Drug Approvals: Expertise and Relationships
blog, Bulk Active Ingredient, Regulatory, Supply Chain Tags: ANDACOVID19drug shortageFDAPAS Dec 29, 2020
Drug approvals are often complex and time-consuming, even for generic versions of approved medications. Some of this complexity is unavoidable for good reasons, especially when it comes to patient safety. Much of the process is specifically designed to minimize the chance that new drugs – or new versions of existing ones – will cause harm.[…]
Solid Dosage Formats Remain the Dominant Pharma Trend
blog, LGM Pharma Tags: beadletscapsulesNexgenOSDFsolid dosagetablets Dec 01, 2020
Oral solid dosage forms (OSDFs), notably capsules and tablets, continue to be the most popular drug form used worldwide. Here are some common questions and insights from Deepak Thassu, VP of LGM Pharma’s R&D and Regulatory Division, about OSDF use and manufacturing. 1. Why do OSDFs dominate the global pharmaceutical market? Solid dosage forms may[…]
LGM Helps Pharma Manage Supply Chain Risks with Added Services Through Nexgen Acquisition
blog, Bulk Active Ingredient, Drug Research & Development API, LGM Pharma, Supply Chain Tags: analytical methods developmentCDMODrug Developmentdrug manufacturingformulations developmentLGM PharmaNexgenpackagingsemi-solidsolid dosesupply chain Nov 02, 2020
COVID-19 has put supply chain risk management practices under the microscope. Coming on the heels of many other, more localized supply issues in the last decade, it has brought about a near-global assessment that supply chains need to be more tightly controlled and redundant – and less dependent on external, at-risk suppliers. In a sense,[…]
Can the U.S. Stop Buying Drugs from China?
blog, Supply Chain Tags: ChinaCOVID-19risk managementsupply chain Oct 04, 2020
The SARS-CoV-2 pandemic has drawn significant attention to just how much US pharmaceutical manufacturers rely on manufacturers outside the United States, both for drug substances and finished dosage drugs. It also has demonstrated the risks associated with global supply chains that are overly reliant on specific regions such as China and India, which may be[…]
LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma
LGM Pharma, Press Release Tags: growth Jul 23, 2020
LGM Pharma’s Expanded Contract Development and Manufacturing Organization (CDMO) Capabilities Will Enable Customers to Accelerate and Optimize the New Product Pathway from Early Development Through Commercialization Boca Raton, Florida, July 27, 2020 – LGM Pharma today announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The[…]
A Look at Reshoring Drug Manufacturing: A Q&A With LGM Pharma’s Hamilton Lenox
blog, Supply Chain Tags: ChinaCOVID-19reshoringsupply chain Jun 08, 2020
When SARS-CoV-2 arrived on American shores this Spring, concerns about overextended drug supply chains already were circulating. The issues at hand weren’t new, by any stretch. Environmental, quality and political actions all had impacted drug imports in the last half-dozen years, causing drug shortages and C-suite anxiety. The global pandemic – and the resultant (albeit[…]
Risk Management Practices to Address Pharmaceutical Sourcing Challenges
LGM Pharma, Supply Chain Tags: Drug Developmentpharmaceutical sourcingsupply chain May 03, 2020
It may seem odd to be discussing sourcing challenges considering the overwhelming evidence we now have of what can happen to global (and even local) supply chains when disaster strikes, but while the coronavirus pandemic certainly has put the spotlight on the risks of global supply chains, it by no means created those risks. Indeed,[…]
